[Search]
[by date] [by subject] [by continent]

SEPSIS/SIRS: Reducing Mortality to Patients & Suppliers

Cambridge Healthtech Institute , Washington, DC USA
October 21, 1996 - October 22, 1996

Program:
The stream of disappointing clinical trials for treatment of sepsis/SIRS is indicative of the complexity of this disorder and the need for a better understanding of what changes are needed to achieve better results. Therapies aimed at inhibition of inflammatory cytokines tend to overlook the dual nature of such a response and the need to precisely determine the timing and extent to which each individual patient's response may be excessive or restricted. There is wide agreement that clinical trials need to be designed to include more homogeneous patient populations, but little consensus on the criteria to use for achieving this goal. Given the difficulty of improving survival of patients, it is surprising that more attention has not been focused on preventive approaches. This program provides a forum for these and other critical questions regarding the direction of drug development and clinical evaluation in this field to be discussed and critiqued.

Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA USA
tel: 617-630-1300
fax: 617-630-1325

Deadline for Abstracts: 8/96

Email for Requests and Registration: chi@healthtech.com


Posted by: Conference Producer Host: cnc127032.concentric.net date: June 28, 96 16:11:52
Generated by meetings and positions 1.0 by Kai Garlipp